| Names | |
|---|---|
| Preferred IUPAC name | 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol |
| Other names | Flagyl Metrogel Noritate Nidagel Elyzol Rozex |
| Pronunciation | /ˌmɛtrəˈnaɪdəˌzoʊl/ |
| Identifiers | |
| CAS Number | 443-48-1 |
| Beilstein Reference | Beilstein Reference: 4120960 |
| ChEBI | CHEBI:6909 |
| ChEMBL | CHEMBL651 |
| ChemSpider | 5467 |
| DrugBank | DB00916 |
| ECHA InfoCard | 100.063.234 |
| EC Number | EC 207-136-1 |
| Gmelin Reference | 82259 |
| KEGG | D00818 |
| MeSH | D008687 |
| PubChem CID | 4173 |
| RTECS number | QU7000000 |
| UNII | 140QMO216E |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C6H9N3O3 |
| Molar mass | 171.15 g/mol |
| Appearance | White to yellowish, crystalline powder |
| Odor | Characteristic |
| Density | 1.45 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 0.1 |
| Vapor pressure | 1.58E-06 mmHg |
| Acidity (pKa) | 2.6 |
| Basicity (pKb) | 2.55 |
| Magnetic susceptibility (χ) | -75.9e-6 cm³/mol |
| Refractive index (nD) | 1.62 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 267.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -380.6 kJ·mol⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -3818 kJ/mol |
| Pharmacology | |
| ATC code | J01XD01 |
| Hazards | |
| Main hazards | May cause cancer, harmful if swallowed, causes serious eye irritation, may cause an allergic skin reaction, suspected of damaging fertility or the unborn child. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | antiinfectives~prohibited_with_alcohol~take_with_food~no_driving |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | > 250°C |
| Autoignition temperature | > 470°C |
| Lethal dose or concentration | LD50 (oral, rat): 5000 mg/kg |
| LD50 (median dose) | > 3.75 g/kg (oral, rat) |
| NIOSH | QW2100000 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 400 mg |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds | Benznidazole Dimetridazole Ornidazole Tinidazole Secnidazole |
| Section | Details & Manufacturer Commentary |
|---|---|
| Product Name | Metronidazole |
| IUPAC Name | 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol |
| Chemical Formula | C6H9N3O3 |
| Synonyms & Trade Names |
Metronidazolum (INN, Latin), 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole. In pharmaceutical raw material handling, alternate nomenclature or local synonyms sometimes appear on shipping or documentation records, typically influenced by the supply region, clinical application, or regulatory submission practice. |
| HS Code & Customs Classification |
HS Code (Harmonized System): 293329 Classified under nitroimidazole derivatives. Regulatory interpretation of the customs code follows the primary functional group. For API grade metronidazole shipments, import/export declarations align with the locally adopted HS mapping, subject to review by customs authorities. Any deviation in declared HS code can result from differences in product form (bulk, finished dosage intermediate), grade, or regional classification norms. |
Metronidazole production involves precision in raw material sourcing to reduce generation of process-specific impurities, primarily associated with the nitro group introduction and imidazole ring construction steps. Purification is tightly linked to the removal of minor byproducts, unreacted intermediates, and residual solvents, where the exact profile depends on the selected synthesis route and purification sequence.
Quality attributes for each batch depend on the intended application—pharmaceutical, veterinary, or in rare instances industrial. Batch consistency is maintained through validated in-process controls, with release criteria defined through internal quality protocols and specific customer requirements. Transport and import/export documentation require exact and technically justified product identification, ensuring regulatory traceability especially for products with applications regulated under drug control laws.
Storage and handling practices must be aligned with the chemical’s physical and chemical sensitivity profile, which is influenced by retained moisture, light exposure, and potential cross-contamination during repackaging or bulk transfer. Packaging selection and sealing practice serve as key quality retention points.
For downstream users, close communication about the specification envelope is essential—minor processing parameter variances can shift impurity levels or alter physical characteristics, which may impact formulation steps or shelf stability depending on the finished dosage form or regional regulatory specification.
Metronidazole typically appears as a crystalline powder. The physical form can range from fine to granular depending on the particle size selected during milling. Color generally falls within the pale beige to light yellow spectrum; occasional off-white batches are observed but can indicate variable crystallinity or minor polymorphic differences, both usually controlled within set appearance parameters. Odor is practically absent in industrial-grade material, and the product does not emit volatile odors under standard storage.
Melting point and other phase transition values follow manufacturer batch records and apply only to pure substance or high-purity grades. Routine control of melting range supports identification and batch verification. Boiling point is not typically relevant in downstream processing since metronidazole decomposes before reaching this state. The flash point is not a practical safety parameter due to low volatility in dry powder form. Density measurements can be relevant for certain formulation applications and vary with compaction and moisture content.
Metronidazole remains chemically stable in finished form when dryness and temperature constraints are respected. Process-derived residual solvents or moisture promote hydrolysis, especially at elevated humidity. Light sensitivity can play a role in color changes or degradation for certain sensitive grades; packaging protocols are thus aligned with exposure risk. Reactivity considerations for manufacturing focus on acidic or basic conditions, which may catalyze breakdown during process or storage.
Solubility in water is grade-dependent and varies with particle size, crystallinity, and agglomeration state. Certain pharmaceutical applications demand rapid dissolution, driving tighter milling and sieving controls. Filtration issues and solution clarity often highlight upstream process impurities. Alcohol and other polar solvent solubilities are referenced for downstream derivatization or residue removal. Solution pH must be adjusted based on end-use specification, as some grades require precise buffering.
Each customer segment—pharma, veterinary, technical—requires distinct quality parameters, typically set out in client-specific or pharmacopoeial monographs. Typical values, such as assay range and residue thresholds, depend on regulatory, application, and market region. Manufacturers maintain product data sheets detailing allowable water content, appearance, and actives concentration, with final release based on agreed contractual terms.
Batch consistency hinges on stringent monitoring of individual related substances, with focus on process-derived nitroso, oxo, and dechlorinated impurities. Actual threshold limits for each impurity respond directly to pharmacopeial or customer requirement. Impurity sources can include raw material traces, process byproducts, thermal decomposition, or post-reaction hydrolysis. Many clients request full impurity breakdown upon lot release.
Assay determination and impurity quantification follow compendial or validated in-house HPLC/GC methods. Identity confirmation relies on infrared spectroscopy or mass spectrometry. Specific test method, validation protocol, and permissible deviation level reflect the final use and regulatory landscape; most finished goods apply pharmacopeial method reference where relevant. Internal laboratories routinely develop and revalidate special methods for new markets or process changes.
Critical raw materials include 2-methyl-5-nitroimidazole and suitable chlorinating agents. Selection focuses on proven purity and traceability; vendor qualification audits and lot pre-inspection flag any variability or compliance risk. Materials undergo full identity, origin, and trace impurity evaluation prior to batch integration. Supply disruptions or shifts in regulatory standards prompt reevaluation or dual-vendor strategies.
Production typically utilizes a chloromethylation pathway, introducing the key methyl sidechain onto a nitroimidazole scaffold, using chloromethylethers or alkylating agents in controlled conditions. Process route depends on available raw feedstock, desired impurity profile, and scale. Current industrial tendencies lean to minimized toxic intermediate use.
In-line sampling and titration confirm charge ratio and reaction completion. Byproduct formation triggers real-time pH or temperature adjustment. Purification involves recrystallization or solvent-switch protocols, designed per customer impurity specification or regional pharmacopeia. Critical control points fall on neutralization steps and solvent removal, as each affects final API purity.
Final release gates depend on multi-parameter checks spanning appearance, assay, impurity, and moisture content. Each batch is trended against historical and customer-specific median values. Release standards accommodate pharmacopoeial, export, and internal controls, and documentation includes full traceability and batch-specific certificates.
Metronidazole can undergo N-alkylation, reduction, and hydrolysis depending on downstream synthesis needs. Sensitivity to acid or base treatment under laboratory conditions can serve as a break-point for process troubleshooting or derivative synthesis.
Commercial reactions often utilize mild organic bases or phase transfer catalysts, kept below decomposition onset temperature. Solvent selection responds to downstream purification and environmental controls, with alcohols and ethers common in controlled environments.
Derivative manufacture for specialized APIs or veterinary actives uses the base molecule as a starting scaffold. Selectivity in side-chain modification or reduction is driven by process design intent and regulatory compliance.
Bulk metronidazole requires protection from excess humidity and direct light exposure. Controlled room temperature and low water vapor conditions help retain crystalline form and assay content. In regions with high ambient moisture, sealed polyethylene liners and inert gas canisters provide added insurance.
Bulk storage uses high-density polyethylene or glass, avoiding reactive metals or non-food-grade plastics. Packaging choices adapt based on final user format and anticipated transport or storage duration. Compatibility checks for extractables/leachables back key export shipments.
Shelf life is defined by gradual assay reduction and color change. Humidity ingress, temperature excursions, or prolonged light exposure accelerate discoloration or active loss. End-users report batch rejection based on off-spec color or content. Internal stability studies support labeled shelf-life claims according to destination market standard.
Classification follows local and export market regulations. Some regions require carcinogenicity notations based on published studies; specific labels vary by jurisdiction and product format.
Standard hazard statements caution against inhalation and skin or eye contact. Precautionary recommendations emphasize handling in ventilated spaces, use of PPE, and avoidance of ingestion or prolonged dermal contact.
Toxicological profile details draw from published literature and validated animal studies. Manufacturing staff receive regular safety training based on acute and chronic exposure findings. Non-pharma grade product is segregated during warehousing and transport.
Workplace exposure guidance references regional workplace safety norms. Air filtration, powder dust suppression, and full personal protective equipment form the core exposure minimization strategy in both packaging and process areas.
Production of metronidazole follows a continuous-response cycle reflecting pharmaceutical sector demand cycles and the effect of regional regulatory timelines. Capacity per site is constrained by reactor size, solvent recovery loop design, active pharmaceutical ingredient (API) cleaning validation schedules, and batch release test turnaround. Shift allocation and seasonal maintenance of critical equipment define short-term surge output. Inventory buffers for consistent output are defined according to customer forecast accuracy and export documentation cycle times.
Lead time for order fulfillment primarily involves active batch scheduling, semiannual plant shutdown planning, and pre-shipment regulatory re-test requirements for pharma-grade material. MOQ depends on product grade—bulk technical grade for veterinary or industrial use generally sets a lower MOQ, while pharmaceutical API grades require higher batch continuity due to registration batch constraints and validation sampling.
Packaging selection directly correlates with the specified grade. Drum and fiberboard keg secondary containment allows bulk shipment for technical grade. Pharma API grades follow moisture and light-protective liners, double-bagged with desiccant, and pharmaceutical regulatory documentation for traceability. Importer-specific traceability or anti-tamper sealing can be incorporated only upon prior agreement and validated through in-house packaging trials.
Transportation and export packaging standards comply with region-specific hazardous substance handling norms. Certificates of analysis and full batch traceability are furnished by internal QA release. Payment terms reflect shipment size, regulatory status, and business history—letter of credit prevalence for new markets, open account after verified performance. Shipping risk assignment (FOB, CFR, DAP) depends on client's logistics capabilities and insurance coverage, agreed in commercial contract negotiation.
Raw material costs for metronidazole track the price behavior of nitration-grade chemicals, hydrogenation catalysts, and chlorinated intermediates sourced primarily from basic organic chemical plants. Russia-Ukraine related disruption in feedstock supply impacted cost volatility for precursors in recent quarters. Local environmental policies for chlorinated waste effluents also altered available production windows, which impacts direct input cost composition.
Product price explains itself through its grade structure—technical, API crude, API purified. Technical grades bear wider impurity spectra so yield higher throughput per batch, resulting in lower conversion costs. API grades require additional purification, multi-step solvent switching, and repeated recrystallizations under GMP compliance, raising energy, labor, and validation costs. Third-party regulatory submission batches carry still higher costs due to document production, archived sample storage, and certified reference standard testing. Packaging certified for pharmaceutical registration may add substantial premiums.
Core drivers are volatility in intermediate and solvent markets, policy changes impacting hazardous waste treatment, and outages in precursor production. For metronidazole, spike periods frequently correlate with step reductions in exporting country's environmental discharge quotas or downstream demand changes following disease outbreak surges which can increase global orders within just one business cycle.
Demand for metronidazole is driven by antimicrobial needs in both human and veterinary fields. Demand profiles in finished dosage form manufacturing locations like India and China drive bulk procurement, while US and EU heavily emphasize traceability, cGMP compliance, and documentation. Regional supply bottlenecks have emerged where import licensing or changing regulatory regimes place sudden new compliance burdens on previously routine shipments.
US and EU importers place heightened emphasis on DMF/CEP/ANDA compatibility and traceability through the active supply chain, making regulatory conformance a price differentiator beyond raw content. Indian and Chinese bulk importers focus on availability and scale, with strong negotiation on lead time and batch size. Japanese buyers hold strict release testing on both impurity profile and heavy metal content. Movement of technical grade into developing markets is most price sensitive and susceptible to secondary distributor markups.
Forward price outlook for 2026, based on cross-industry sourcing data and major raw material trend analysis, projects steady upward pressure where compliance regimes for pharma intermediates intensify and energy policy interventions persist. Short-term volatility could spike if major API hubs in Asia contend with regulatory checks or raw material bottlenecks. Historical price datasets from industry group purchasing organizations and spot check imports inform these projections; data triangulation follows batch-by-batch procurement cost surveys and regulatory import bulletins.
Recent quarters showed temporary supply disruptions linked to stricter wastewater discharge enforcement at key Asian facilities. Parallel API import testing rules implemented by both India and China extended clearing time for several shipments, backing up inventory at secondary ports. The raw material cost spike followed a burst in demand during regional gastrointestinal disease outbreaks.
Europe continued rolling review of nitrosamine detection protocols for all APIs, including metronidazole, raising in-process control costs for compliance. Chinese and Indian plants updated control logic for multi-source impurity surveillance, now recording retention samples for extended periods, which adds direct inspection time and documentation workload.
Plant operations teams have responded with cross-training for batch record documentation, upgraded online impurity monitoring during key synthesis and purification steps, and expanded multi-shift quality sampling for regulatory documentation. Investment in compliant packaging lines and validation of alternate raw material suppliers aims to balance price volatility and compliance. Flexible batch size configuration helps bridge between large bulk purchasers and regulatory demand for full batch traceability.
Metronidazole supports several industrial sectors but two main fields drive grade differentiation: pharmaceuticals and veterinary applications. Pharmaceutical grade is processed to meet stringent human health regulatory requirements, with every batch undergoing full traceability and well-defined impurity profiling. Veterinary and animal health sectors use industrial grades focused on stability and cost-effective composition, supporting mass animal health campaigns where scale often takes priority over ultra-high purity.
Other niche uses, such as research and development or as a reference material in chemical synthesis, adopt specialized grades defined by purpose-driven specifications drawn directly from end-user validation protocols.
| Sector | Grade | Key Specifications | Primary Concerns |
|---|---|---|---|
| Human Pharmaceuticals | Pharmaceutical Grade | Impurity profile, microbiological control, full regulatory documentation | Patient safety, compliance to pharmacopeia, batch traceability |
| Veterinary/Feed | Technical/Veterinary Grade | Cost-targeted specifications, relaxed impurity limits versus pharmaceutical | Consistency, residue monitoring, feed compatibility |
| Research & Reference | Research Grade | Lot-to-lot reproducibility, specified assay, custom impurity limits | Analytical reliability, sample documentation, supply flexibility |
Quality priorities rotate around assay value, impurity content, moisture content, particle size, and document package. High-purity pharmaceutical batches often rely on additional purification to limit genotoxic impurities and residual solvents to levels enforceable by current ICH guidelines. Veterinary and technical grades show higher batch-to-batch tolerance, but downstream formulation or premix stability still depends on moisture and free-flowing characteristics. In research, lot documentation and homogeneity receive heightened scrutiny. Each sector sets its own release criteria based on the downstream use and regional legal framework.
Start by stating the final product use. Human medicines require pharmaceutical grade by default. Veterinary clients often focus on feed use or bulk finished product preparation, which affects grade selection.
Clarify if the target market or region mandates compliance with EP/USP/JP or a national veterinary standard. Pharmaceutical use always brings full GMP documentation obligations, while animal health may need only supplier audit records and basic CoA.
Pharmaceutical grade maintains a lower impurity profile through intensified purification steps and closer impurity monitoring. Veterinary grade tolerates broader impurity ranges as dictated by animal safety reviews. Custom research batches prioritize documentation and defined impurity cut-off points as per customer request.
Larger orders with relaxed purity specifications benefit from economies of scale using industrial or technical grades. Pharmaceutical and reference grade require more process control, so scaling up brings diminishing returns without prior factory coordination.
Validation at the customer's own site resolves trial-formulation uncertainty and facilitates official batch approval. Our lab supports sample preparation tailored to project-specific assays and impurity investigation.
Production always focuses on raw material qualification, process monitoring, and validation against customer’s end-use performance. Batch consistency and impurity minimization stay central to every supply decision.
Our metronidazole production sites operate under documented quality management systems. Certification status—including ISO 9001 or equivalent—is determined according to location and customer requirement. Auditable processes control raw material qualification, batch tracing, equipment calibration, and deviation response. Ongoing internal audits monitor all departments. Each certification remains valid through scheduled third-party assessment cycles as required by regulatory authorities or customer audits.
Local or export markets may require registration or certification under regionally mandated pharmacopeia or chemical standards. Product supplied for regulated pharmaceutical use adheres to compliance schemes such as GMP certification, as requested for audit or regulatory submission. For each customer, we review the intended application, grade, and jurisdiction, then determine which certifiable schemes or monographs apply to the supplied batch. Full traceability for each lot supports investigation and audit trail requirements.
Classic controlled batch documentation covers certificate of analysis, batch record review, impurity profile, and where applicable, stability trends and safety data. Specific reporting formats follow customer and regulatory requirements, often going beyond minimum compliance and referencing raw material data back to suppliers. Customers with regulatory or audit needs can request retrospective batch review or regulatory-supporting technical files as supply chain traceability or additional substantiation.
Capacity planning ties directly to contracted volume expectations, producer site scheduling, and inventory management set at each stage of manufacture. For larger clients, buffer stock and campaign-based production smooth out spikes in demand. Smaller customers benefit from pooled production runs or shipment grouping. Terms and contracts structure cooperation lengths, pricing windows, and resupply intervals with the flexibility to re-negotiate as volume or regulatory requirements change.
Core metronidazole production occurs in dedicated or validated multipurpose reactors, depending upon the batch size, application, and cross-contamination risk profile. Site infrastructure enables substantial output, with redundancy in solvent recovery, utilities, and raw material stocks. Production capacity remains matched to contracted volume brackets, and siteholds negotiate off-take agreements to ensure supply during market or logistics disruptions. Batch reservation schemes let strategic clients receive supply assurance when market volatility influences raw input availability.
Customers who require pre-purchase sample assessment initiate the application by specifying grade, intended end-use, and local regulatory expectations. Technical documentation (CoA, SDS, where appropriate) accompanies shipped sample. Sampling protocol depends on volume, market, and downstream use-case: pharmaceutical evaluation, process trial, or secondary technical evaluation. Feedback from sampled material shapes subsequent full-scale supply, with manufacturing record references retained for match-back.
Each procurement interaction is matched to the customer’s risk profile, regulatory environment, and recurring demand scope. Consignment models, buffer inventory, and deferred or milestone-tied purchase orders operate as options. For sudden demand changes, rapid batch scheduling or shipment rescheduling may be triggered subject to plant capacity. Technical support is available throughout, including batch documentation tailoring, compliance update cycles, and product complaint investigation where deviations in performance or conformity arise. We flex cooperation modes by mutually agreed documentation, quality, delivery, and pricing requirements.
In industrial manufacturing, process intensification and impurity profiling occupy most of the development resources for metronidazole. The primary challenge involves managing nitroso and other genotoxic impurities during synthesis and downstream purification. Experienced operators pay special attention to solvent recovery and byproduct management, since raw material selection and reaction temperature control strongly influence impurity pathways.
Efforts in continuous flow synthesis have also gained momentum, where the main goal is to achieve reduced solvent loading, improved batch reproducibility, and minimizing human error in critical stages. Crystallization optimization—tailored for meeting pharmacopeia requirements—remains a dynamic area, especially when customers request a specific polymorph or particle size for formulation compatibility.
Beyond well-established pharmaceutical and veterinary sectors, some technical work explores metronidazole’s role in specialty coatings and industrial biocides. For such uses, customers often require distinct purity profiles and granulation, prompting customized downstream processing. These niche demands can stretch standard process capabilities, requiring flexibility in both scale and process design.
Synthesis routes involving nitromethane or glyoxal introduce unique control points for side reactions, leading to process selection based on local regulatory and environmental factors. Key breakthroughs have come from advances in secondary purification stages, particularly the adoption of membrane filtration and solid phase extraction to target trace-level impurities.
Polymorphic consistency has presented issues across multi-tonne campaigns, pushing manufacturers toward a blend of real-time PAT (Process Analytical Technology) controls and traditional offline testing for each batch. The management of humidification and particle attrition during handling directly impacts downstream compression or blending performance and cannot be decoupled from both process and application needs.
Demand for pharmacopeia-grade metronidazole fluctuates in correlation with global antimicrobial utilization patterns. Major regulatory changes in emerging markets are likely to drive order surges for compliant material in the short-to-medium term. Veterinary and topical formulation customers often trigger process revalidation cycles when local pharmacopoeia or environmental disposal regulations shift.
Grade differentiation will become more pronounced as industrial and specialty users place custom orders with specific impurity and particle specifications. Capacity utilization rates reflect both market demand volatility and region-specific registration cycles. Actual delivered product portfolios depend on contract structure, customer-released standards, and evolving regional certifications.
Continuous processing, solvent minimization, and the roll-out of advanced in-line analytics will continue to shrink the delta between batch reproducibility in laboratory and plant. Process validation and equipment modernization in older facilities accelerate as regulatory scrutiny increases. Green chemistry principles influence not only raw material sourcing, but also solvent selection and waste stream handling.
Compliance with REACH and similar frameworks drives the adoption of alternative catalysts, lower toxicity reagents, and improved solvent recovery rates. Manufacturers with flexible reaction setups or developed solvent reclamation infrastructure can lower the lifecycle environmental burden more effectively. Waste valorization—transforming process byproducts into sellable industrial intermediates—represents an active R&D track, with success depending on downstream market access and purity tolerance of secondary users.
Customer technical teams gain detailed pathway maps for product grade selection, allowing for targeted troubleshooting at the raw material or process adjustment level. With each inquiry, case-specific solvent, impurity, or stability advice takes into account historical batch records, current equipment aging, and local regulatory trends.
Support teams provide direct guidance during scale-up or when modifying formulation parameters post-market. Advice incorporates real plant data, including common challenges such as particle aggregation during bulk transfer, or the impact of minor solvent residue variability in downstream pharmaceutical compaction. Process modification recommendations always tie back to achievable in-plant controls.
Batch traceability and consistency are non-negotiable points. Finished product undergoes staged release, with final shipment predicated on quality conformance to batch-specific analytical results. Deviation management involves joint investigation between customer and quality control, including full transparency for impurity root-cause analysis and internal CAPA (Corrective and Preventive Actions) procedures. Shelf life, repackaging logistics, and batch extension requests receive direct assessment from production and QA teams based on historical storage performance and latest analytical trending, avoiding generic qualification statements.
In our facility, Metronidazole production runs on validated batch processes, monitored at every stage. Crude intermediates and finished product both undergo targeted impurity profiling and verification through HPLC, plus batch-level moisture and particle size checks. Every lot leaves the plant backed by a record of test results, not just an internal standard. This discipline matters for downstream users seeking reliable process inputs with predictable performance.
Bulk Metronidazole finds its way into several segments. Most of our volume supports pharmaceutical manufacturers developing human and veterinary formulations, where consistent active content and purity command attention. Animal health operations use it in products for protozoal and anaerobic infections. Some technical buyers in the fine chemical sector route it toward complex synthesis or as a reference standard in laboratory analysis. The industrial value of the ingredient depends on reproducible assay and low residual solvents—non-negotiable for regulated markets and high-output lines alike.
Rigorous in-process control sets the foundation before any final test result makes the certificate. Each critical stage in synthesis—starting material qualification, filtration, crystallization—brings its own checkpoints. Analysts work batch-by-batch, not just blending lots to mask variability. Every shipment leaves with a complete batch record and traceable testing trail, matched to purchaser requirements for import, registration, or regulatory submission. Our role as producer means no backtracking for batch substitutions; what ships matches paperwork, always.
We package Metronidazole at our own handling stations, offering fiber drums, lined bags, or custom industrial containers based on buyer requirements and transit needs. Technical materials for formulation move in dedicated lots, with packaging clean-outs documented and inspected. High-volume output allows us to meet bulk contracts, repeat demand, and staggered call-off schedules for global buyers. Experienced logistics support handles export documentation and regulatory alignment at dispatch, ensuring shipments clear customs barriers without delay.
Our in-house application specialists address solubility, reactivity, and process integration questions for each grade shipped. Experienced technical teams work directly with formulators and manufacturing engineers to support incorporation into downstream products. Buyers with specialized needs for impurity management or enhanced dissolution get rapid feedback based on actual laboratory data, not vague assurances.
Direct purchase from our plant shortens the supply path, reducing risk of quality drift and missed delivery windows. Distributors and contract manufacturers count on batch-level reporting and the stability of a controlled origin. Procurement audiences benefit from volume-based pricing, stable supply agreements, and transparency that stands up to audit. Our production runs 12 months a year, eliminating guesswork on availability and shortening lead times for repeat orders.
As a direct manufacturer of pharmaceutical chemicals, our focus on Metronidazole starts long before it reaches formulators or finished dosage producers. Knowledge of its precise mechanisms and pharmacokinetic profile informs every decision—right from raw material sourcing through synthesis, purification, and quality control. The expectations for batch reproducibility in antimicrobial agents like Metronidazole remain high, especially given its widespread application against anaerobic bacterial and protozoal infections.
Metronidazole’s mechanism stands out among synthetic nitroimidazole derivatives. Its efficacy comes from nitroreduction, a process driven by chemical reduction of its nitro group inside susceptible microorganisms. This reaction only occurs under anaerobic or microaerophilic conditions, where reduction of the nitro group yields reactive intermediates. These intermediates then disrupt microbial DNA structure, inhibiting nucleic acid synthesis.
From our perspective as a chemical manufacturer, controlling impurity levels and ensuring the correct stereochemistry ensures that the synthesized Metronidazole performs as intended. Incomplete or off-target intermediates during chemical reactions may introduce contaminants that can alter pharmacological activity or increase risk of side effects. For this reason, our QC lab conducts detailed spectroscopic and chromatographic analyses on every production batch.
Metronidazole is almost completely absorbed following oral administration, meaning plasma levels reach predictable concentrations. The molecule demonstrates a high degree of tissue penetration, reaching fluids across the body including the central nervous system. Most of the compound remains unbound to plasma proteins, which is significant when preparing bulk active for pharmaceutical use—free drug correlates with biological activity on pathogens.
We have seen from customer feedback and published clinical data that hepatic metabolism represents the primary clearance route for Metronidazole, producing both active and inactive metabolites. These processes do not occur at random; they rely on consistent chemical identity and purity. Our facilities maintain strict protocols for protecting against batch-to-batch variation, ensuring the final product’s pharmacokinetic properties align with international standards.
Renal and biliary excretion clear both parent drug and metabolites. Since some clients produce formulations for use in patients with impaired liver or kidney function, our documentation includes detailed impurity profiles and support for pharmacovigilance investigations. This transparency contributes to accurate dosing adjustments and long-term safety monitoring in end-user markets.
Our role as the primary producer goes beyond raw synthesis. Understanding Metronidazole’s chemical behavior allows us to advise on formulation stability and interaction with excipients—lessons learned from decades of scaled-up manufacturing lines. If issues such as precipitation or reduced solubility arise in pilot blends, our technical sales team can review batch analytical data and propose adjustments to meet the requirements of finished dosage forms.
Clients frequently ask for extended impurity characterization, particularly as global GMP frameworks demand increasing transparency and traceability. Our facility logs every synthetic step, and retains reference samples from all batches for retrospective quality reviews. Drawing from this archive, we support partners facing questions about degradation kinetics or specific metabolite profiles in clinical settings.
As regulatory expectations rise globally for APIs, our first-hand experience with Metronidazole gives us confidence in its quality for use in compounded, veterinary, and human medicines. We always encourage open technical discussions around its production, storage, and application—and our team remains available for in-depth, batch-specific conversations upon request.
In the chemical industry, it pays to be clear about how Metronidazole makes its way from the reactor to your door. Our facility produces Metronidazole using in-house controlled synthesis, with output tested batch by batch. Feedback from global clients points to packaging, order size, and lead time as the critical details for smooth procurement.
Years of direct shipment to pharmaceutical formulators, compounding centers, and contract manufacturers have shaped our packaging choices. The most common request is for fiber drums lined with two layers of polyethylene. Each drum typically holds 25 kilograms of Metronidazole API. Smaller units, such as 10 kg or 5 kg sealed double PE bags, are also available for pilot projects or accelerated R&D runs. All packaging carries clear batch numbers, production dates, and COA details for full traceability.
Occasionally, a customer requires custom packaging—such as smaller bag units for pre-blending or bulk containers for large scale formulation. Our team can develop alternative packaging after a technical review. Stability and contamination prevention drive our packaging validation, not just regulatory compliance. Experience shows that solid film liners outperform single-layer solutions in the long haul of ocean freight or multi-modal logistics.
Production scheduling and shipment efficiency guide our minimum order policy. For standard Metronidazole, the floor stands at 25 kg, matching a drum pack. Running small batches below this threshold forces an atypical start-up pattern on the line, which can strain QC turnarounds or lead to unnecessary overage. Large buyers rarely see this as a challenge, but for labs or contract research work, we occasionally arrange exceptions. Customers scaling up from lab to pilot can access smaller lots when production windows allow, and we provide precise material traceability at every stage.
Our plant operates continuous production during high-demand periods. A typical lead time for a made-to-order batch runs from 10 to 14 working days, including quality analysis and packaging. Full container or multi-drum loads tend to be quicker, as line changeover and documentation prep can be managed in parallel. Lead times can stretch during annual maintenance, regulatory audits, or when the active ingredient demand spikes worldwide, but we keep clients updated on these cycles.
Immediate stock may be available for recurring customers under supply contracts. Regular forecasting and blanket orders allow us to reserve production blocks, reducing wait times and minimizing uncertainty for critical production timelines. We work closely with logistics partners to book vessel space and customs clearance in advance, which helps shave several days off the delivery chain if demand surges unexpectedly.
Handling the process end-to-end means our technical support, documentation package, and shipment tracking remain under factory control. Customers get batch samples for evaluation, and each delivery includes a full set of test results. We don’t cut corners by shuffling drums between warehouses or re-labeling bulk stock; every order ships with original seal and documentation direct from our site.
In summary, our direct approach to packaging, scalable order quantities, and transparent lead times bring confidence to buyers. Open communication and steady production rhythm mark our operation, ensuring both large and small clients get reliable service—straight from the source, without intermediary confusion.
Temperature and humidity critically shape the physical stability of metronidazole. Years of hands-on experience with our own production reinforce the importance of cool, dry, and consistent storage. Our metronidazole leaves our facility strictly packed to shield it from light, heat, and dampness. Exposure above 25°C or to high humidity accelerates degradation and influences assay values. On our factory floor, controlled-environment warehousing is not negotiable. Staff monitor temperature and relative humidity continuously, locking in quality from synthesis through distribution.
Every batch of metronidazole passes an accelerated and real-time stability program before we set a formal shelf-life. For our standard production lots, a two- to five-year unopened shelf-life holds based on retained potency, color, and purity data. We sample and test materials over time using validated HPLC and microbiological methods per pharmacopoeia monographs. Proper storage in the original sealed packaging ensures minimal risk of contamination or moisture pickup. Handling bulk containers once opened requires prompt use or re-sealing in accordance with our SOPs.
Any pharmaceutical ingredient left our docks faces regulator scrutiny across borders. We prepare every shipment of metronidazole with a technical package including certificate of analysis, material safety data sheet compliant with GHS, and certificates confirming compliance with major pharmacopoeias such as USP or EP when required. Our compliance team also registers drug master files (DMFs) and submits ingredient dossiers to various authorities, ensuring traceability from plant to port. Customs and pharmaceutical regulators often inspect these documents, so accuracy takes precedence over volume.
With global regulations increasing, we have adapted to country-specific import requirements. For many destinations, we issue written statements on GMO status, residual solvents, and allergens. Since nitroimidazoles can fall under controlled substance regulations in certain jurisdictions, pre-clearance and supporting toxicology data form part of our proactive compliance process.
Direct control over manufacturing and logistics helps us respond rapidly to unplanned events. We perform container selection, sealing, and labeling in-house with batch-specific tracking. For temperature excursions or customs delays, trained compliance staff document exception handling according to GDP and PIC/S guidelines. This approach builds trust with pharmaceutical formulators and regulatory inspectors worldwide.
Responding to real-world shipping challenges requires more than just meeting minimum spec sheets. We continually strengthen monitoring equipment in our warehouses and engage in regular stability re-testing. These investments in process and documentation make sure metronidazole retains its certified characteristics until it reaches your facility or laboratory.
Supplying metronidazole globally is more than exporting a compound. Consistency, robust documentation, and first-hand manufacturing oversight drive our reliability. As regulations evolve, we raise our own practices to meet higher expectations—not only to pass an audit but to ensure our partners receive material they can depend on.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
